Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New developments in angiogenesis: a major mechanism for tumor growth and target for therapy.

× No keyword cloud information.

13 in total

Review 1. The role of angiogenesis in rheumatoid arthritis: recent developments.

Authors: A E Koch
Journal: Ann Rheum Dis Date: 2000-11 Impact factor: 19.103

2. Actions of the protein kinase WNK1 on endothelial cells are differentially mediated by its substrate kinases OSR1 and SPAK.

Authors: Hashem A Dbouk; Lauren M Weil; G K Sachith Perera; Michael T Dellinger; Gray Pearson; Rolf A Brekken; Melanie H Cobb
Journal: Proc Natl Acad Sci U S A Date: 2014-10-31 Impact factor: 11.205

Review 3. Angiogenesis as a target in rheumatoid arthritis.

Authors: A E Koch
Journal: Ann Rheum Dis Date: 2003-11 Impact factor: 19.103

4. Design of Nanoparticle-Based Carriers for Targeted Drug Delivery.

Authors: Xiaojiao Yu; Ian Trase; Muqing Ren; Kayla Duval; Xing Guo; Zi Chen
Journal: J Nanomater Date: 2016 Impact factor: 2.986

5. MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma.

Authors: Swadesh K Das; Sujit K Bhutia; Belal Azab; Timothy P Kegelman; Leyla Peachy; Prasanna K Santhekadur; Santanu Dasgupta; Rupesh Dash; Paul Dent; Steven Grant; Luni Emdad; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal: Cancer Res Date: 2012-12-10 Impact factor: 12.701

Review 6. Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications.

Authors: S A Cohen; M Trikha; M A Mascelli
Journal: Pathol Oncol Res Date: 2000 Impact factor: 3.201

Review 7. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics.

Authors: Stephanie D Steichen; Mary Caldorera-Moore; Nicholas A Peppas
Journal: Eur J Pharm Sci Date: 2012-12-20 Impact factor: 4.384

8. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.

Authors: Jill M Siegfried; Christopher T Gubish; Mary E Rothstein; Cassandra Henry; Laura P Stabile
Journal: J Thorac Oncol Date: 2012-03 Impact factor: 15.609

Review 9. Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.

Authors: T E Clark; N Edom; J Larson; L J Lindsey
Journal: Drug Saf Date: 2001 Impact factor: 5.228

Review 10. Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.

Authors: Shizhu Chen; Keni Yang; Ruslan G Tuguntaev; Anbu Mozhi; Jinchao Zhang; Paul C Wang; Xing-Jie Liang
Journal: Nanomedicine Date: 2015-12-17 Impact factor: 5.307